MedTrace Logo

Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects

NCT07049107 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-03-16

No results posted yet for this study

Summary

This study is a single-center, open-label, sequential drug interaction study

The primary objectives are:

To evaluate the pharmacokinetic effects of HRS-8427 injection on the liver drug enzymes CYP2B6 substrate bupropion and CYP3A4 substrate midazolam in healthy subjects.

Conditions

  • Health Volunteer

Interventions

DRUG

HRS-8427

HRS-8427

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-06-23
Primary Completion
2025-07-21
Completion
2025-07-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07049107 on ClinicalTrials.gov